Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Zoom Video Communications, Inc. (ZM) Price & Performance

Novo Nordisk A/STrade
Zoom Video Communications, Inc.Trade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Zoom Video Communications, Inc. — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: Novo Nordisk A/S is far larger — about 6× Zoom Video Communications, Inc.'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Zoom Video Communications, Inc. for 92 Days on average.

NVOZM
Market Cap
$165.31B$27.62B
Volume
11,432,8383,913,188
Sector
HealthTechnology
52-Week High
$63.98$111.88
52-Week Low
$35.29$72.72
Typical Hold Time
116 Days92 Days
Enterprise Value
$179.56B$20.43B
Dividend Yield
4.71%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.

NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.

Zoom Video Communications, Inc.

Zoom (ZM) trades at $94.67, down 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a net income margin of 65.19% and ROE of 32.14% for 2025. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 missed. Analyst consensus price target is $118.08, implying significant upside. News highlights include AI product launches and board appointments, supporting growth initiatives.

The outlook for ZM is positive given its robust fundamentals, earnings momentum, and Wall Street's bullish stance. Key opportunities include AI-driven revenue growth and strategic investments. Risks involve competitive pressures, execution challenges, and market volatility. The stock presents a compelling case for growth investors, though careful monitoring of quarterly performance is advised.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVO
96% Buy4% Sell
Avg holding period · 116 Days
ZM
0% Buy100% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →

About Zoom Video Communications, Inc.

Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.

Read more on ZM →